BioAtla, Inc. (BCAB)

BioAtla Statistics

Total Valuation

BioAtla has a market cap or net worth of $13.74 million. The enterprise value is $11.61 million.

Market Cap	13.74M
Enterprise Value	11.61M

Important Dates

The next estimated earnings date is Thursday, March 26, 2026, after market close.

Earnings Date	Mar 26, 2026
Ex-Dividend Date	n/a

Share Statistics

BioAtla has 74.26 million shares outstanding. The number of shares has increased by 16.89% in one year.

Current Share Class	74.26M
Shares Outstanding	74.26M
Shares Change (YoY)	+16.89%
Shares Change (QoQ)	+0.41%
Owned by Insiders (%)	8.10%
Owned by Institutions (%)	11.33%
Float	60.60M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.54

Current Ratio	0.54
Quick Ratio	0.46
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-105.08%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	3,164.45%
Weighted Average Cost of Capital (WACC)	6.96%
Revenue Per Employee	n/a
Profits Per Employee	-$1.06M
Employee Count	61
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -43.22% in the last 52 weeks. The beta is 1.06, so BioAtla's price volatility has been similar to the market average.

Beta (5Y)	1.06
52-Week Price Change	-43.22%
50-Day Moving Average	0.35
200-Day Moving Average	0.52
Relative Strength Index (RSI)	40.00
Average Volume (20 Days)	2,385,682

Short Selling Information

The latest short interest is 2.70 million, so 3.63% of the outstanding shares have been sold short.

Short Interest	2.70M
Short Previous Month	6.61M
Short % of Shares Out	3.63%
Short % of Float	4.45%
Short Ratio (days to cover)	0.82

Income Statement

Revenue	n/a
Gross Profit	-46.73M
Operating Income	-65.69M
Pretax Income	-64.71M
Net Income	-64.71M
EBITDA	-65.11M
EBIT	-65.69M
Earnings Per Share (EPS)	-$1.15

Balance Sheet

The company has $8.32 million in cash and $6.18 million in debt, with a net cash position of $2.14 million or $0.03 per share.

Cash & Cash Equivalents	8.32M
Total Debt	6.18M
Net Cash	2.14M
Net Cash Per Share	$0.03
Equity (Book Value)	-31.24M
Book Value Per Share	-0.53
Working Capital	-8.31M

Cash Flow

Operating Cash Flow	-57.07M
Capital Expenditures	n/a
Free Cash Flow	-57.07M
FCF Per Share	-$0.77

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

BioAtla does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-16.89%
Shareholder Yield	-16.89%
Earnings Yield	-470.73%
FCF Yield	-415.18%

Analyst Forecast

The average price target for BioAtla is $1.00, which is 440.54% higher than the current price. The consensus rating is "Hold".

Price Target	$1.00
Price Target Difference	440.54%
Analyst Consensus	Hold
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-10.59%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BioAtla has an Altman Z-Score of -60.91 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-60.91
Piotroski F-Score	1